Heroin-induced locomotion and mesolimbic dopamine release is unchanged in mice lacking the ORL.1 receptor gene

Brain Research

Volumn 953, Issue 1-2, 2002, Pages 276-280

  Murphy, Niall P ^a,c   Lam, Hoa A ^a   Chen, Zhenping ^b   Pintar, John E ^b   Maidment, Nigel T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Dopamine; Locomotion; Mesolimbic; Nociceptin; Opiate; Orphanin FQ

Indexed keywords

DIAMORPHINE; DOPAMINE; NOCICEPTIN; NOCICEPTIN RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVELOPMENT; DIALYSATE; DOPAMINE RELEASE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; GENOTYPE; LOCOMOTION; MESOLIMBIC DOPAMINERGIC SYSTEM; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RECEPTOR GENE; WILD TYPE;

ANALGESICS, OPIOID; ANIMALS; DOPAMINE; HEROIN; LIMBIC SYSTEM; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; OPIOID PEPTIDES; RECEPTORS, OPIOID;

EID: 0037145704     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03398-X     Document Type: Article

References (23)

1. Bals-Kubik R., Herz A., Shippenberg T.S. Beta-endorphin-(1-27) is a naturally occurring antagonist of the reinforcing effects of opioids. Naunyn Schmiedeberg's Arch. Pharmacol. 338:1988;392-396.
2. Bals-Kubik R., Herz A., Shippenberg T.S. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology. 98:1989;203-206.
3. Chefer V., Czyzyk T., Pintar J., Shippenberg T.S. Dopaminergic neurotransmission in the nucleus accumbens of kappa-opioid receptor (KOR) knockout mice: an in vivo microdialysis study (Abstract). 31st Meeting of the International Narcotics Research Conference, Sun16, 2000.
4. Ciccocioppo R., Panocka I., Polidori C., Regoli D., Massi M. Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Berlin). 141:1999;220-224.
5. Ciccocioppo R., Angeletti S., Sanna P.P., Weiss F., Massi M. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur. J. Pharmacol. 404:2000;153-159.
6. Clarke S., Chen Z., Hsu M.S., Pintar J., Hill R., Kitchen I. Quantitative autoradiographic mapping of the ORL1, mu-, delta- and kappa-receptors in the brains of knockout mice lacking the ORL1 receptor gene. Brain Res. 906:2001;13-24.
7. Devine D.P., Reinscheid R.K., Monsma F.J. Jr., Civelli O., Akil H. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. 727:1996;225-229.
8. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
9. Di Giannuario A., Pieretti S., Catalani A., Loizzo A. Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats. Neurosci. Lett. 272:1999;183-186.
10. Franklin K.B.J., Paxinos G.T. The Mouse Brain in Stereotaxic Coordinates. 1997;Academic Press, New York.
11. Funada M., Suzuki T., Narita M., Misawa M., Nagase H. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology. 32:1993;1315-1323.
12. Iwamoto E.T. Place-conditioning properties of mu, kappa, and sigma opioid agonists. Alcohol Drug Res. 6:1985;327-339.
13. Kest B., Hopkins E., Palmese C.A., Chen Z.P., Mogil J.S., Pintar J.E. Morphine tolerance and dependence in nociceptin/orphanin fq transgenic knock-out mice. Neuroscience. 104:2001;217-222.
14. Lutfy K., Do T., Maidment N.T. Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats. Psychopharmacology (Berlin). 154:2001;1-7.
15. Maidment N.T., Brumbaugh D.R., Rudolph V.D., Erdelyi E., Evans C.J. Microdialysis of extracellular endogenous opioid peptides from rat brain in vivo. Neuroscience. 33:1989;549-557.
16. Martin-Fardon R., Ciccocioppo R., Massi M., Weiss F. Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats. Neuroreport. 11:2000;1939-1943.
17. Mollereau C., Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides. 21:2000;907-917.
18. Mucha R.F., Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology. 86:1985;274-280.
19. Murphy N.P., Maidment N.T. Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J. Neurochem. 73:1999;179-186.
20. Murphy N.P., Ly H.T., Maidment N.T. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience. 75:1996;1-4.
21. Murphy N.P., Lee Y., Maidment N.T. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res. 832:1999;168-170.
22. Norton C.S., Neal C.R., Kumar S., Akil H., Watson S.J. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J. Comp. Neurol. 444:2002;358-368.
23. Tsuji M., Takeda H., Matsumiya T., Nagase H., Narita M., Suzuki T. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci. 68:2001;1717-1725.